149 related articles for article (PubMed ID: 30882253)
21. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease.
Polak J; Hajkova H; Haskovec C; Cechova H; Marinov I; Mikulenkova D; Markova J; Markova M; Vitek A; Valkova V
Neoplasma; 2013; 60(1):74-82. PubMed ID: 23067220
[TBL] [Abstract][Full Text] [Related]
22. Dynamic changes in the level of WT1 as an MRD marker to predict the therapeutic outcome of patients with AML with and without allogeneic stem cell transplantation.
Liu H; Wang X; Zhang H; Wang J; Chen Y; Ma T; Shi J; Kang Y; Xi J; Wang M; Zhang M
Mol Med Rep; 2019 Sep; 20(3):2426-2432. PubMed ID: 31257540
[TBL] [Abstract][Full Text] [Related]
23. Anti-apoptotic quinolinate phosphoribosyltransferase (QPRT) is a target gene of Wilms' tumor gene 1 (WT1) protein in leukemic cells.
Ullmark T; Montano G; Järvstråt L; Jernmark Nilsson H; Håkansson E; Drott K; Nilsson B; Vidovic K; Gullberg U
Biochem Biophys Res Commun; 2017 Jan; 482(4):802-807. PubMed ID: 27889611
[TBL] [Abstract][Full Text] [Related]
24. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias.
Menssen HD; Renkl HJ; Rodeck U; Maurer J; Notter M; Schwartz S; Reinhardt R; Thiel E
Leukemia; 1995 Jun; 9(6):1060-7. PubMed ID: 7596170
[TBL] [Abstract][Full Text] [Related]
25. Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias.
Siehl JM; Thiel E; Heufelder K; Snarski E; Schwartz S; Mailänder V; Keilholz U
Br J Haematol; 2003 Oct; 123(2):235-42. PubMed ID: 14531904
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
Kwon M; Martínez-Laperche C; Infante M; Carretero F; Balsalobre P; Serrano D; Gayoso J; Pérez-Corral A; Anguita J; Díez-Martín JL; Buño I
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
[TBL] [Abstract][Full Text] [Related]
27. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
28. Wilms tumour 1 peptide vaccine as a cure-oriented post-chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse.
Nakata J; Nakae Y; Kawakami M; Morimoto S; Motooka D; Hosen N; Fujiki F; Nakajima H; Hasegawa K; Nishida S; Tsuboi A; Oji Y; Oka Y; Kumanogoh A; Sugiyama H
Br J Haematol; 2018 Jul; 182(2):287-290. PubMed ID: 28542830
[No Abstract] [Full Text] [Related]
29. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy.
Cilloni D; Messa F; Arruga F; Defilippi I; Gottardi E; Fava M; Carturan S; Catalano R; Bracco E; Messa E; Nicoli P; Diverio D; Sanz MA; Martinelli G; Lo-Coco F; Saglio G
Haematologica; 2008 Jun; 93(6):921-4. PubMed ID: 18443273
[TBL] [Abstract][Full Text] [Related]
30. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
[TBL] [Abstract][Full Text] [Related]
31. The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia.
Owen C; Fitzgibbon J; Paschka P
Hematol Oncol; 2010 Mar; 28(1):13-9. PubMed ID: 20013787
[TBL] [Abstract][Full Text] [Related]
32. Wilms' tumor gene (WT1) expression correlates with vascular epithelial growth factor (VEGF) in newly acute leukemia patients undergoing chemotherapy.
Iranparast S; Assarehzadegan MA; Heike Y; Hossienzadeh M; Khodadadi A
Asian Pac J Cancer Prev; 2014; 15(21):9217-23. PubMed ID: 25422204
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
Zidan MA; Kamal Shaaban HM; Elghannam DM
Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521
[TBL] [Abstract][Full Text] [Related]
34. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Molecular Relapse by Cessation of Immunosuppression After Hematopoietic Stem Cell Transplantation in Pediatric FLT3-ITD AML Monitored by WT1 Expression in Peripheral Blood.
Løvvik Juul-Dam K; Ifversen M; Guldborg Nyvold C; Hansen M; Hasle H
J Pediatr Hematol Oncol; 2019 Jul; 41(5):417-419. PubMed ID: 31238330
[TBL] [Abstract][Full Text] [Related]
36. [Dynamic assessment of WT1 for predicting the relapse of acute myeloid leukemia patients with MLL rearrangements after hematopoietic stem cell transplantation].
Liu XX; Kong J; Pan SA; Liu J; Qin YZ; Chang YJ; Wang Y; Zhang XH; Xu LP; Huang XJ; Zhao XS
Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):785-787. PubMed ID: 36709175
[No Abstract] [Full Text] [Related]
37. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies.
Miyagawa K; Hayashi Y; Fukuda T; Mitani K; Hirai H; Kamiya K
Genes Chromosomes Cancer; 1999 Jun; 25(2):176-83. PubMed ID: 10338002
[TBL] [Abstract][Full Text] [Related]
38. "Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow.
Ochsenreither S; Fusi A; Busse A; Bauer S; Scheibenbogen C; Stather D; Thiel E; Keilholz U; Letsch A
J Immunother; 2011 Jan; 34(1):85-91. PubMed ID: 21150716
[TBL] [Abstract][Full Text] [Related]
39. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.
Lange T; Hubmann M; Burkhardt R; Franke GN; Cross M; Scholz M; Leiblein S; Al-Ali HK; Edelmann J; Thiery J; Niederwieser D
Leukemia; 2011 Mar; 25(3):498-505. PubMed ID: 21135860
[TBL] [Abstract][Full Text] [Related]
40. The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis.
Long J; Fang S; Dai Q; Liu X; Zhu W; Wang S
Oncotarget; 2016 May; 7(22):32079-87. PubMed ID: 26992216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
